Name:
36765172.pdf
Size:
304.9Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.Issue Date
2023
Metadata
Show full item recordAbstract
NoneCitation
Howell A, Howell SJ. Tamoxifen evolution. British journal of cancer. 2023 Feb;128(3):421-5. PubMed PMID: 36765172. Pubmed Central PMCID: PMC9938251. Epub 2023/02/11. eng.Journal
British Journal of CancerDOI
10.1038/s41416-023-02158-5PubMed ID
36765172Additional Links
https://dx.doi.org/10.1038/s41416-023-02158-5Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41416-023-02158-5
Scopus Count
Collections
Related articles
- The limits of tamoxifen.
- Authors: Kennedy MJ
- Issue date: 2002 Jan-Mar
- Breast cancer patients can stop tamoxifen after 5 years.
- Authors: Gottlieb S
- Issue date: 2001 Jul
- Tamoxifen reduces breast cancer by a third in high risk women.
- Authors: Mayor S
- Issue date: 2002 Sep 21
- Tamoxifen for the treatment and prevention of breast cancer: an update.
- Authors: Afflitto L
- Issue date: 2000 Winter
- Tamoxifen for early breast cancer.
- Issue date: 2001 Jun 21-27